TY - JOUR
TI - Cost per PASI-75 responder of calcipotriol plus betamethasone dipropionate cutaneous foam versus nonbiologic systemic therapies for the treatment of plaque psoriasis in seven European countries
AU - Balak, D.M.W.
AU - Carrascosa, J.-M.
AU - Gregoriou, S.
AU - Calzavara-Pinton, P.
AU - Bewley, A.
AU - Antunes, J.
AU - Nyeland, M.E.
AU - Viola, M.G.
AU - Sawyer, L.M.
AU - Becla, L.
JO - Journal of Dermatological Treatment
PY - 2021
VL - 32
TODO - 7
SP - 701-708
PB - Taylor and Francis Ltd.
SN - 0954-6634, 1471-1753
TODO - 10.1080/09546634.2019.1707754
TODO - apremilast;  betamethasone dipropionate plus calcipotriol;  dimethyl fumarate;  etretin;  methotrexate;  betamethasone;  betamethasone-17,21-dipropionate;  calcipotriol;  calcitriol;  dermatological agent, adult;  Article;  Belgium;  clinical effectiveness;  comparative effectiveness;  controlled study;  cost effectiveness analysis;  drug cost;  drug dose escalation;  drug dose increase;  drug dose titration;  European Medicines Agency;  foam;  follow up;  Greece;  human;  Italy;  major clinical study;  Netherlands;  observational study;  Portugal;  Psoriasis Area and Severity Index 75;  psoriasis vulgaris;  Spain;  systemic therapy;  topical treatment;  treatment duration;  treatment response;  United Kingdom;  drug combination;  psoriasis;  treatment outcome, Betamethasone;  Calcitriol;  Dermatologic Agents;  Drug Combinations;  Humans;  Psoriasis;  Treatment Outcome
TODO - Purpose: To compare the short-term cost and effectiveness of calcipotriol/betamethasone dipropionate (Cal/BD) cutaneous foam against nonbiologic systemics in psoriasis patients for whom oral systemic or topical therapy is considered appropriate in seven European countries. Methods: Matching-adjusted indirect comparisons of four-week PASI-75 responses of Cal/BD foam were performed versus 12-week responses of methotrexate, acitretin, fumaric acid esters (FAE) and 16-week responses of apremilast. Analyses took a payer perspective and included drug, physician visit and monitoring costs. Results: In all countries, Cal/BD foam generated the lowest cost per responder (CPR). Against methotrexate, apremilast and acitretin, Cal/BD foam generated response for less than €190 in Italy, €195 in Portugal, €216 in Greece, £218 in the United Kingdom, €250 in Belgium, €319 in Spain, and €359 in the Netherlands. Relative to treatment with FAE, Cal/BD foam resulted in response for less than €298, €430, €382 and £262 in Belgium, the Netherlands, Spain and the United Kingdom, respectively. For Cal/BD foam, apremilast and FAE, total costs were driven by drug costs; for methotrexate and acitretin, by monitoring. Conclusions: Driven by its lower costs and high response rates, Cal/BD foam is likely to be a cost-effective option over the short-term in the investigated psoriasis population. © 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.
ER -